image credit- freepik
Shanghai Henlius Biotech has entered into a strategic collaboration with Sandoz, a global leader in generics and biosimilars, covering up to 10 proposed monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar products or components developed by Henlius.
The parties have also signed collaboration terms for an initial three agreed products and an option for one additional asset.
In April 2025, the two companies entered into an exclusive commercialisation partnership for HLX13, Henlius' proposed ipilimumab biosimilar, across 46 countries and regions including Europe and the United States. This new agreement further deepens the existing oncology biosimilars collaboration between the two parties.
Under the strategic collaboration agreement, Henlius will grant Sandoz exclusive rights for registration and commercialisation outside China for up to 10 partnered products worldwide. Most of the partnered products are currently at early stages of development, and the two parties will collaborate closely from the early stages of project development. Based on a multi-product portfolio framework, the collaboration will cover key stages across the product lifecycle, including product development, regulatory submissions, manufacturing, launch, commercialization and lifecycle management.
Henlius will leverage its integrated biologics platform to undertake the development, manufacturing and supply of the partnered products, thereby accelerating the development and translation of early-stage molecules.
Sandoz will pay Henlius an upfront payment, relevant milestone payments and a non-refundable option fee totaling up to $322 million. In 2026, the total invoiced amount expected for Henlius is up to $100.5 million.
